Orphanet Journal of Rare Diseases (Jul 2023)

Treatment of relapsing multiple sclerosis in Hungary – consensus recommendation from the Hungarian neuroimmunology society

  • Cecilia Rajda,
  • Csilla Rózsa,
  • Andrea Mike,
  • Gábor Lovas,
  • Zsolt Mezei,
  • Gábor Jakab,
  • Péter Ács,
  • Gábor Rum,
  • Magdolna Simó,
  • Zita Jobbágy,
  • Zita Bíró,
  • Anita Trauninger,
  • Piroska Imre,
  • Klotild Mátyás,
  • István Deme,
  • Zsolt Illés,
  • Tunde Csepany

DOI
https://doi.org/10.1186/s13023-023-02789-0
Journal volume & issue
Vol. 18, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Multiple sclerosis (MS) may impact quality of life, careers and family plans of the affected individuals. The current treatments with disease modifying therapies aim to prevent people with MS (pwMS) from disability accumulation and progression. Different countries have different reimbursement policies resulting in inequalities in patient care among geographical regions. Access to anti-CD20 therapies for relapsing MS is restricted in Hungary because therapy of individual cases only is reimbursed. In the light of the latest research and national guidelines, 17 Hungarian MS experts agreed on 8 recommendations regarding relapsing pwMS using the Delphi round method. Strong agreement (> 80%) was achieved in all except one recommendation after three rounds, which generated a fourth Delphi round. The experts agreed on treatment initiation, switch, follow-up and discontinuation, as well as on special issues such as pregnancy, lactation, elderly population, and vaccination. Well-defined national consensus protocols may facilitate dialogue between policymakers and healthcare professionals and thus contribute to better patient care in the long run.

Keywords